ClinicalTrials.gg
RecruitingNCT07531719Updated Nov 4, 2026

A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)

An observational study in Spinal Muscle Atrophy, sponsored by Hoffmann-La Roche. Recruiting at 2 sites in Egypt. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hoffmann-La Roche · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
Up to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche — 1 open to participants now, 4 under way, none of them phase 3. Muscular Atrophy, Spinal · Hoffmann-La Roche.

Started
2026
the only one that year
Observational
2 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, this one is the only one that started in 2026, is one of 2 observational ones, and was the 18th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

1 of the 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: Up to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Muscular Atrophy, Spinal by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This multicenter, non-interventional, prospective study with a retrospective component aims to evaluate the real-world clinical outcomes, safety profile, and motor function improvements of Risdiplam treatment in participants with Type I and Type II Spinal Muscle Atrophy over 24 months of treatment.

The study will allow retrospective collection of medical history data and previous participants visits from the medical records.

03

Conditions studied

  • Spinal Muscle Atrophy
04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants must have a confirmed diagnosis of 5q-autosomal recessive SMA type I or type II with at least two survival motor neuron 2 (SMN2) copies for which Risdiplam is prescribed as per the SmPC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maximum age to be 6 months for type I participants and 5 years for type II participants at the time of diagnosis.
  • Participants must start/have started treatment with Risdiplam within 6 months of diagnosis.
  • Participant to be receiving adequate nutrition and hydration at index date, in the opinion of the Investigator.
  • Participant to be adequately recovered from any acute illness at the time index date.

Exclusion criteria

Exclusion Criteria:

  • Participants not receiving treatment for disease with Risdiplam according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling.
  • Participants not receiving the Roche studied medicinal product, but a biosimilar.
  • Concomitant or previous administration in any drug or device study.
  • Concomitant or previous administration of approved treatment for SMA other than Risdiplam.
  • Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases at index date.
  • Participants requiring invasive ventilation or tracheostomy at index date.
  • Participants requiring awake non-invasive ventilation due to respiratory insufficiency or with awake hypoxemia with or without ventilator support or with history of respiratory failure or severe pneumonia, and have not fully recovered their pulmonary function at the time of index date.
  • Severe contractures of joints of lower limbs and upper limbs at the time of index date.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Risdiplam Observational Arm

    Data will be collected before, during and after treatment from participants who receive risdiplam treatment according to standard of care and Summary of Product Characteristics (SmPC). Participant data will be collected only during routine clinical interactions, with no additional study visits mandated.

06

What researchers measure

Primary outcomes

  1. Change From Index Date in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Score at Month 12

    CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by the World Health Organization (WHO). Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam.

    Time frame: Baseline, Month 12

  2. Change From Index Date in Hammersmith Functional Motor Scale Expanded (HFMSE) Score at Months 12

    HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the gross motor function measure (GMFM) with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function. The index date (D1) is when the participant was administered the first dose of Risdiplam.

    Time frame: Baseline, Months 12

Secondary outcomes

  1. Change From Index Date in CHOP-INTEND Score at Month 24

    CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam.

    Time frame: Baseline, Month 24

  2. Percentage of Participants with CHOP-INTEND Score Improvement ≥ 4 Points Compared to Index Date at Months 12 and 24

    CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam.

    Time frame: Baseline, Months 12 and 24

  3. Percentage of Participants with CHOP-INTEND Score ≥ 40 at Months 12 and 24

    CHOP-INTEND assessment is performed for participants aged \<2 years or aged \>2 years who are not able to sit \> 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal orientated items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes.

    Time frame: At Months 12 and 24

  4. Change From Baseline in HFMSE Score at Month 24

    HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the GMFM with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function. Baseline visit correspond with the index date (D1) where the participant was administered the first dose of Risdiplam.

    Time frame: Baseline, Month 24

  5. Number of Participants who Require Ventilatory Assistance

    Invasive ventilation and non-invasive ventilation due to respiratory insufficiency. Participants on permanent ventilation and when using it as temporary respiratory support will be assessed.

    Time frame: Up to 2 years follow-up per participant

  6. Duration of Ventilation

    Number of hours spent per day of non-invasive or invasive ventilation. Duration for both permanent ventilation and when used as temporary respiratory support will be assessed.

    Time frame: Up to 2 years follow-up per participant

  7. Time Until Permanent Ventilation

    Time until permanent ventilation is defined as ≥ 16 hours of non-invasive ventilation per day or intubation for \> 21 consecutive days in the absence of, or following the resolution of, an acute reversible event or tracheostomy.

    Time frame: Up to 2 years follow-up per participant

  8. Overall Survival at Month 24

    Time frame: At Month 24

  9. Ventilation-free Survival

    Assessed by duration of time from a specified index date until the initiation of permanent ventilation.

    Time frame: Up to 2 years follow-up per participant

  10. Change From Baseline in Growth Pattern

    Growth patterns will be compared to standardized growth charts.

    Time frame: Up to Month 24

  11. Number of Participants With Musculoskeletal Abnormalities

    Musculoskeletal abnormalities include scoliosis, kyphosis or other deformities

    Time frame: Up to Month 24

  12. Time to Loss of Swallowing Function Assessed by the Study Physician

    Time frame: Up to Month 24

  13. Bulbar Function as Assessed by the Study Physician Versus Baseline

    Bulbar function measures the ability to feed orally, chew, and ability to swallow versus baseline data. It also assesses the speaking and crying functions of the participant.

    Time frame: Up to Month 24

  14. Number of Participants With Adverse Events (AE) Serious Adverse Events (SAE)

    Data for incidence, seriousness, severity, and relatedness of all AEs reported or documented in medical notes by physicians during the safety observation period will also be reported.

    Time frame: Up to 2 years follow-up per participant

07

Study locations

2 of 2 sites recruiting
  • Neurology Department, Ain Shams University Hospitals
    Cairo, 11566, Egypt
    Recruiting
  • Air Force Specialized Hospital
    Cairo, DUMMY_VALUE, Egypt
    Recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 15, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07531719
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 22, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Reference Study ID Number: ML45655 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion